Peptide analogues containing a 7-membered lactam ring

The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P-R1-R2-R3-R4, in which P, R1, R2, R3, and R4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

PEPTIDDERIVATE

PEPTID SIMILAR ONE, THE ONE SIEBENGLIEDRIGEN LACTAM RING CONTAINING

PEPTID OF DERIVATIVES

PEPTID AND PSEUDOPEPTID DERIVATIVES.

Compound storage

POLYPEPTIDE COMPOUNDS

The invention relates to a polypeptide of formula I: R1-CO-A1-A2-A3-A4-A5-A6-Q I wherein each of the generic terms is disclosed in full in the specification and includes: R1 is a 5- or 6-membered unsaturated heterocyclic ring which contains one, two or three nitrogen atoms, which ring may optionally bear one or two substituents A1 is a direct link to A2, or is His or D-His; A2 is Trp or MeTrp; A3 is Ala or MeAla; A4 is Val; A5 is Gly or D-Ala; A6 is His or Lys(Z); and Q is a group of the formula -A7.R2 in which A7 is Leu or MeLeu and R2 is hydroxy, amino, (1-3C)alkylamino or (13C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino. The compounds possess antagonist properties against bombesin-like peptides and are of value in the treatment of malignant disease in warm-blooded animals.

PEPTID SYNTHESIS AT FIRM PHASE

PIPERAZIN-4-PHENYL-DERIVATE AS INHIBITORS OF THE RECIPROCAL EFFECT BETWEEN MDM2 AND MDM2

PROCESS FOR MAKING PEPTIDES CONTAINING AZA-AMINO ACIDS

PH.36403 PROCESS FOR MAKING PEPTIDES A process for the solid phase synthesis of peptides containing a C-terminal aza-amino acid, for example the decapeptide goserelin, which comprises: (i) reacting an active ester or imidazolide of an N-protected aza-amino acid either with an appropriate reactive solid support in the case of the synthesis of a peptide containing a C-terminal aza-amino acid, or with a peptide which is attached to a solid support in the case of the synthesis of a peptide containing a non-C-terminal aza-amino acid; (ii) carrying out further conventional solid phase peptide synthesis steps to add sequentially further amino acids, to form a peptide with the required amino acid sequence bound to the solid support; (iii) cleaving the peptide from the solid support, and optionally (iv) reacting the product so formed with hydrazine to remove any acyl groups which have been formed on serine, arginine, tyrosine, threonine or hydroxyproline during the synthesis.

PEPTIDE DERIVATIVES

The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-Q, in which P, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, and Q have the various meanings defined herein and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Peptide derivatives

PEPTIDE AND PSEUDOPEPTIDE DERIVATIVES

Inhibitors of peptide binding to mhc class ii proteins

The invention concerns pharmacologically useful peptide derivatives of the formula (I): P-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-Q, and pharmaceutically acceptable salts thereof, wherein either AA3 together with AA4, or AA4 together with AA5, or AA6 together with AA7 form a group of formula (II):in which Ra is selected from hydrogen and (1-4C)alkyl, and the remainder of AA1, AA2, AA3, AA4, AA5, AA6, AA7, and AA8 are L-amino acid residues; P is a hydrophobic residue; and Q is OH, NH2 or NRcRd. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds, and pharmaceutical compositions containing them, in treating MHC class II dependent T-cell mediated autoimmllne or inflammatory diseases, such as rheumatoid arthritis.

Peptide derivatives

PROCESS FOR MAKING PEPTIDES CONTAINING AZA-AMINO ACIDS

A process for the solid phase synthesis of peptides containing a C-terminal aza-amino acid, for example the decapeptide goserelin, which comprises: (i) reacting an active ester or imidazolide of an N-protected aza-amino acid either with an appropriate reactive solid support in the case of the synthesis of a peptide containing a C-terminal aza-amino acid, or with a peptide which is attached to a solid support in the case of the synthesis of a peptide containing a non-C-terminal aza-amino acid; (ii) carrying out further conventional solid phase peptide synthesis steps to add sequentially further amino acids, to form a peptide with the required amino acid sequence bound to the solid support; (iii) cleaving the peptide from the solid support, and optionally (iv) reacting the product so formed with hydrazine to remove any acyl groups which have been formed on serine, arginine, tyrosine, threonine or hydroxyproline during the synthesis.

PEPTIDE DERIVATIVES

The invention concerns pharmaceutically useful peptide derivatives of the formula (I): P-R1-R2-R3-R4, in which P, R1, R2, R3, and R4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

SOLID PHASE SYNTHESIS OF PEPTIDES CONTAINING C-TERMINAL AZA-AMINO ACID AMIDE

PURPOSE: To obtain the subject peptide for treating a prostatic cancer, mammary cancer, etc., by bringing an N-protected aza-amino acid active ester, etc., into reaction with a suitable reactive solid carrier followed by subsequent reaction of another amino acid, then cleaving the peptide from this solid carrier. CONSTITUTION: In the solid phase synthesis method of the peptide contg. at least one kind of the aza-amino acid, the active ester or imidazolide the N- protected aza-amino acid is brought into reaction with the suitable reactive solid carrier in the case of the synthesis of the peptide contg. the C-terminal aza-amino acid and is brought into reaction with the peptide bonded to the solid carrier in the case of the synthesis of the peptide contg. the non-C-terminal aza-amino acid and further, a customary solid phase peptide process for successively adding another amino acid is executed to form the peptide having the desired amino acid sequence bonded to the solid carrier and in addition ...

PEPTID DERIVATE

POLYPEPTIDE COMPOUNDS

PEPTID ANALOGE, DIE EINEN SIEBENGLIEDRIGEN LACTAMRING ENTHALTEN

Peptide derivatives

Process for making peptides

Peptide derivatives

Peptide derivatives

Novel peptide derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing then are useful in treating MHC class II dependent T-cell method autoimmune or inflammatory diseases, such as rheumatoid arthritis.

Peptid-Synthese an fester Phase

Polypeptide.

Peptide derivatives

PEPTIDE ANTAGONISTS OF BOMBESIN & BOMBESIN LIKE PEPTIDES

Peptide derivatives

POLYPEPTIDE COMPOUNDS

Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and 53

WEARABLE JOINT TRACKING DEVICE WITH MUSCLE ACTIVITY AND METHODS THEREOF

A system for utilizing wearable, wireless-connected sensors that record both IMU and EMG muscle activity for rehabilitation with kinematic monitoring is disclosed. The system runs an efficient quaternion-based complementary filter that estimates the sensor orientation while correcting for estimate drift and constraining magnetometer estimates to only influence heading. The difference in the two sensor orientations is used to estimate the joint angle, which can be further improved with joint axis estimation. Thus, successful tracking of joint angle and muscle activity in a home environment can be accomplished with the sensors and a smartphone. Further, a system utilizing these sensors may include video-capable cameras configured for capturing a video of a pose of the user, and a game framework executable by a processor in communication with the sensors and the cameras. The system may include a game framework configured to utilize a pose trajectory and one or more joint angles determined using the sensors to provide biofeedback to a user. 1. A system for utilizing wearable sensors to record muscle activity and provide biofeedback for rehabilitation with kinematic monitoring , comprising:a plurality of sensors aligned on a limb of a user, each of the plurality of sensors including an inertial measurement unit (IMU) for generating inertial data and a plurality of electromyography (EMG) electrodes for generating muscle EMG data; and estimate a pose of the limb of the user, by estimating an attitude of a first sensor and an attitude of a second sensor of the plurality of sensors,', 'estimate a joint angle of the limb, the joint angle measured as a rotation magnitude about an inferred axis of the limb defined by the attitude of the first sensor and the attitude of the second sensor, and', 'execute a therapy application, the therapy application configured to utilize the EMG data, and pose and joint angle of the limb as estimated from the plurality of sensors to detect ...

Polypeptide.

PIPERAZIN-4-PHENYL-DERIVATE ALS INHIBITOREN DER WECHSELWIRKUNG ZWISCHEN MDM2 UND MDM2

PEPTIDDERIVATE

Peptide derivatives

The invention concerns pharmaceutically useful peptide derivatives of the formula (I): P—R 1 —R 2 —R 3 —R 4 , in which P, R 1 , R 2 , R 3 and R 4 have various meanings defined herein, and their pharmaceutically salts, and pharmaceutically compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell medicated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

PEPTIDDERIVATE

PEPTID DERIVATE

INHIBITORE DER PEPTIDBINDUNG AN MHC CLASS II PROTEINE

PORTABLE AND WEARABLE ELECTROMYOGRAPHIC BIOFEEDBACK FOR SPINAL CORD INJURY TO ENHANCE NEUROPLASTICITY

Various embodiments of a platform for providing electromyographic biofeedback are disclosed. The platform includes a sensor device having an IMU and electrodes for simultaneous tracking of IMU and EMG activity. The IMU and EMG data may be generated and leveraged in conjunction with a gaming application provided to a user while engaged to the sensor device to provide biofeedback therapy for rehabilitation. 1. A system , comprising:one or more wearable sensor devices that engage skin tissue proximate to a muscle, the one or more wearable sensor devices detecting signal data resulting from activity of a muscle;a processor in operative communication with the plurality of wearable sensor devices, wherein the processor is configured for processing electromyography data and inertial data defined by the signal data; anda mobile device in operative communication with the processor, wherein the mobile device is configured for executing instructions including:receiving the electromyography data and the inertial data of the signal data;executing a game program, wherein the signal data is taken as input to the game program; andadapting the game program based on a set of qualities pertaining to the signal data.2. The system of claim 1 , wherein the one or more wearable sensor devices topically adhere to a paretic muscle of a user.3. The system of claim 1 , wherein the one or more wearable sensors record the signal data throughout a day.4. The system of claim 1 , wherein the one or more wearable sensor devices are operable for storing the signal data.5. The system of claim 1 , wherein the one or more wearable sensor devices include an inertial measurement unit including at least one magnetometer claim 1 , at least one gyroscope claim 1 , and at least one accelerometer.6. The system of claim 5 , wherein the processor is integrated along the one or more wearable sensor devices and is configured to measure a baseline attitude of each of the wearable sensor devices with a user's joint ...

INHIBITORE DER PEPTIDBINDUNG AN MHC CLASS II PROTEINE

PEPTID ANALOGE, DIE EINEN SIEBENGLIEDRIGEN LACTAMRING ENTHALTEN

Peptid-Synthese an fester Phase

PIPERAZIN-4-PHENYL-DERIVATE ALS INHIBITOREN DER WECHSELWIRKUNG ZWISCHEN MDM2 UND MDM2

Peptit türevleri.

POLYPEPTIDE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION USED IN TREATMENT OF DISEASES OR MEDICAL CONDITION ARRANGED BY BOMBESIN OR BOMBESIN-LIKE PEPTIDE

NEW MATERIAL: A compd. of the formula [wherein R1 is H, (phenyl substd.) 1-6C alkyl, (substd.) 2-6C alkanoyl, 4-6C cycloalkoxycarbonyl, etc.; A1 is a direct bond to A2, Gly, Arg, etc.; A2 is a direct bond to A3, Gly, Pro, etc.; A3 is a direct bond to A4, Lys, etc.; A4 is His, etc.; Ab is Trp, etc.; A6 is Ala, etc.; A7 is Val, etc.; A8 is Gly, etc.; A9 is His, etc.; Q is A10.R2 (in which A10 is Leu, etc.; R2 is OH, amino, etc.), phenyl-1-3C alkylamino, etc.]. USE: The compd. is useful as a therapeutic drug for diseases arranged by bombesin or bombesin-like peptide. PROCESS: An amide linkage for bonding polyamide having a carboxylic group or its reactive deriv. on one end and an amino group on the other end is formed in such a way that polypeptide having the chain of the formula is obtained, and then if necessary a protecting group is removed. COPYRIGHT: (C)1989,JPO ...

Peptide analogues containing a 7-membered lactam ring

The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P-R1-R2-R3-R4, in which P, R1, R2, R3, and R4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Compound storage

The invention relates to adsorbing chemical samples onto inert carriers to form highly stable free flowing solid for long term storage in, for example, a proprietary compound collection.

Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and p 53

A compound of formula (1), wherein: R5 is hydrogen, C1-4alkyl, R6CH2- or R6C(O)-; R6 is aryl, heteroaryl, heterocyclyl, aminoC3-6alkyl, N-(C1-4alkyl)aminoC3-6alkyl, NN-(diC1-4alkyl)aminoC3-6alkyl, or R7; wherein the aryl, heteroaryl or heterocyclyl rings may be optionally substituted with up to three substituents independently selected from nitro, C1-4alkyl, C1-4alkoxy, halo, (C1-4alkyl)sulfanyl, C1-4alkoxycarbonyl, N-(C1-4alkyl)carbamoyl, NN-(diC1-4alkyl)carbamoyl, N-(C1-4alkyl)amino or NN-(diC1-4alkyl)amino; wherein R7 is either a group or formula (2) or formula (3); and wherein L1, L2, L3, L4, R1, R2, R3, R4, R8, R9, R10, R11, R12, R13, A1, n, p, q, r and s are as defined herein. The compounds of formula (1) inhibit the interactions between MDM2 and p53 and may be useful in the treatment of cancers.

Peptit türevleri

POLYPEPTIDE COMPOUND, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR CURING DESEASE AND MEDICAL SYMPTOM CAUSED BY BOMBESIN OR BOMBESIN-LIKE PEPTIDE

NEW MATERIAL: A compound (salt) of the formula [wherein R1 is a five-membered or six-membered unsatd. heterocycle containing 1 to 3 N; A1 is a directed bond, His, D-Gln, Leu or the like; A2 is Trp, Lue, Lys or the like; A3 is Ala, Pro or the like; A4 is Val, Leu or the like; A5 is Gly, Sar or the like, A6 is His, Val, Leu or the like; Q is A7-R2 (in which A7 is Leu, Ile, Pro or the like; and R2 is OH, NH2, a 1-3C alkylamino or the like) or the like]. USE: Therapeutic agent for malignant diseases such as human lung small cell carcinoma. PROCESS: Compd. of the formula are obtd. by, for example, bonding a C-terminated amino acid, in which an α-amino group or the like is protected, to a solid support such as a hydroxymethylated resin, removing the α-amino-protecting group, then repeating the operation of bonding an amino acid, in which an α-amino group or the like is protected, followed by the removal of the protecting group according to the amino acid arrangement of the intended polypeptide ...

One-photon integrated neurophotonic systems

An apparatus and method for detecting functional cellular activity within a volume of a tissue. The method includes inserting a three-dimensional array of optical emitters and optical detectors into a volume of a tissue, where the tissue volume includes one or more cells labeled with an optical reporter of cellular activity; illuminating the one or more cells with photons from the optical emitters of the three-dimensional array to generate optical signals from the optical reporter that labels the one or more cells; and detecting the optical signals using the optical detectors of the three-dimensional array, where the illumination includes one-photon excitation of the optical reporter.

Triac array

Thyristors A1-A3 of one conductivity type formed as an array in a first semiconductor body A are respectively connected in parallel with thyristors B1-B3 of the opposite conductivity type formed as an array in a second semiconductor body B to produce an array of triacs. In each body the thyristors are separate except for a common anode or cathode region and terminal connection, and are formed in an epitaxial layer divided by PN junction isolation regions on a substrate of opposite conductivity type. The thyristors may be constructed to be triggered by gating signals of either polarity and the semiconductor bodies are mounted on a heat sink C. <IMAGE>

POLYPEPTIME RELATIONSHIPS, PROCEDURES FOR PREPARING THOSE PHARMACEUTICAL AGENTS CONTAINING THESE

peptide Derivatives

Peptide and pseudopeptide derivatives

Compounds of the formula:wherein R¹ stands for an alk-2-enyl radical of not more than 5 carbon atoms or a furylmethyl radical, R² stands for an alk-2-enyl or alkyl radical of not more than 5 carbon atoms or a furylmethyl radical, >N-A, B, D, E and F stand for defined amino acid or aza-amino-acid residues, and in particular one or both of B and D stand(s) for an amino acid residue of the formula -NH.C(1-3C alkyl)(1-3C alkyl).CO- or a similar residue, and X stands for -OR⁷ or -NR⁷R⁸, wherein R⁷ and R⁸, which may be the same or different, stand for hydrogen or a (1-4C)alkyl radical, and wherein the linkages are all conventional peptide linkages or in the case of D-E the peptide linkage is replaced by the group -CH₂S-, and pharmaceutically-acceptable salts thereof. Processes for the manufacture of the compounds. Pharmaceutical compositions comprising one of the compounds and a pharmaceutically-acceptable diluent or carrier. The compounds are selective opiate δ-receptor antagonists.

Peptide derivatives,which inhibit t-cell activation, process for producing them and pharmaceutical compositions containing them

A találmány (I) általános képletű új peptidszármazékokra ésgyógyászatilag alkalmazható sóikra vonatkozik, amelyek az autoimmunbetegségek és hasonló rendellenességek kezelésében hasznosíthatófarmakológiai aktivitással rendelkeznek. A képletben P egy hidrofóbmaradékot jelent, R1 egy öt L-aminosavból álló szekvenciát ésugyanakkor R3 egyetlen L-aminosavat jelent, vagy R1 egy három L-aminosavból álló szekvenciát, és ugyanakkor R3 egy három L-aminosavbólálló szekvenciát jelent, R2 egy (II) vagy (III) általános képletűcsoportot jelent, amelyekben Ra és Rb egymástól függetlenülhidrogénatomot vagy 1–4 szénatomos alkilcsoportot, A pedigmetiléncsoportot (CH2) vagy oxigénatomot képvisel, és R4hidroxilcsoportot, aminocsoportot vagy egy –NRcRd képletű csoportotjelent, amelyben Rd hidrogénatomot vagy 1–4 szénatomos alkilcsoportotképvisel, és Rc jelentése 1–4 szénatomos alkil-, 2-karbamoil-ciklopentil-, 2-piridil-- metil-, 4-karbamoil-ciklohexil-, 4-karbamoil-ciklohexil-metil-, 3-karbamoil-fenil-, 4-karbamoil-fenil-,4-(karbamoil- metil)-fenil-, 4-(karboxi-metil)-fenil-, 4-(metoxi-karbonil-metil)-fenil- vagy 2-morfolino-etil-csoport, vagy Rc egy –A1–G1 képletű csoportot jelent, vagy R4 1-piperazinil-, 4-metil-1-piperazinil-, 4-amidino-1-piperazinil-, 4-[2-(2-hidroxi-etoxi)-etil]-1-piperazinil- vagy 1-- piperidilcsoportot vagy a 4-es helyzetbenkarboxil-, karbamoil-, N-(2-amino-etil)-karbamoil- vagy N-(4-amino-bu-til)-karbamoil-csoporttal szubsztituált 1-piperidilcsoportot jelent,vagy R4 egy 1–6 aminosavból álló szekvenciát vagy annak amidjátjelenti. ŕ The present invention relates to novel peptide derivatives of formula (I) and pharmaceutically acceptable salts thereof, which possess pharmacological activity in the treatment of autoimmune diseases and related disorders. In the formula, P represents a hydrophobic residue, R1 represents a sequence of five L-amino acids, and while R3 represents a single L-amino acid sequence, or R1 represents a sequence of three L-amino acids, and R3 ...

Automatic storage and retrieval system

Bird feeder

Peptide derivatives,which inhibit t-cell activation, process for producing them and pharmaceutical compositions containing them

A találmány (I) általánős képletű, új peptidszármazékőkra ésgyógyászatilag alkalmazható sóikra vőnatkőzik, amelyek az aűtőimműnbetegségek és hasőnló rendellenességek kezelésében hasznősíthatófarmakőlógiai aktivitással rendelkeznek. A képletben P egy hidrőfóbmaradékőt jelent, R1 egy öt L-aminősavból álló szekvenciát ésűgyanakkőr R3 egyetlen L-aminősavat jelent, vagy R1 egy hárőm L-aminősavból álló szekvenciát és űgyanakkőr R3 egy hárőm L-aminősavbólálló szekvenciát jelent, R2 egy (II) vagy (III) általánős képletűcsőpőrtőt jelent, R4 hidrőxilcsőpőrtőt, aminőcsőpőrtőt vagy egy -NRcRdképletű csőpőrtőt jelent, amelyben Rd hidrőgénatőmőt vagyalkilcsőpőrtőt képvisel, és Rc jelentése alkil-, 2-karbamőil-ciklőpentil-, 2-piridil-metil-, 4-karbamőil-ciklőhexil-, 4-karbamőil-ciklőhexil-metil-, 3-karbamőil-fenil-, 4-karbamőil-fenil-, 4-(karbamőil-metil)-fenil-, 4-(karbőxi-metil)-fenil-, 4-(metőxi-karbőnil-metil)-fenil- vagy 2-mőrfőlinő-etil-csőpőrt, vagy Rc egy -A1-G1 képletű csőpőrtőt jelent, ahől A1 jelentése 3-7 szénatőmősalkiléncsőpőrt, vagy (1) -A2-B2- képletű csőpőrt, (2) -A3-B3-C3-képletű csőpőrt, és űgyanakkőr G1 -N=C[N(RP)2]2 csőpőrtőt jelent, vagyA1 -A4-B4- képletű csőpőrtőt jelent, és űgyanakkőr G1 2-mőrfőlinő-etil- vagy 4-[2-(2-hidrőxi-etőxi)-etil]-piperazin-1-il-csőpőrtőtjelent, vagy R4 1-piperazinil-, 4-metil-1-piperazinil-, 4-amidinő-1-piperazinil-, 4-[2-(2-hidrőxi-etőxi)-etil]-1-piperazinil- vagy 1-piperidil-csőpőrtőt vagy a 4-es helyzetben karbőxil-, karbamőil-, N-(2-aminő-etil)-karbamőil- vagy N-(4-aminő-bűtil)-karbamőil-csőpőrttalszűbsztitűált 1-piperidil-csőpőrtőt jelent, vagy R4 egy 1-6aminősavból álló szekvenciát vagy annak amidját jelenti. ŕ The present invention relates to novel peptide derivatives of the general formula (I) and their pharmaceutically acceptable salts which have pharmacological activity useful in the treatment of cooling immune diseases and related disorders. In the formula, P represents a hydrophobic residue, R1 represents a sequence of ...

Peptide derivative use and process for the production of the same pharmaceutical composition process for the treatment of an autoimmune or inflammatory disease mediated by mhc class ii dependent t-cell and protected or unprotected amino acid or a salt thereof

Peptide derivatives

Automatic storage and retrieval system

Polypeptide compounds

Neuromedin c derivatives having bobesin-inhibiting properties

Wearable joint tracking device with muscle activity and methods thereof

Wearable joint tracking device with muscle activity and methods thereof

A system for utilizing wearable, wireless-connected sensors that record both IMU and EMG muscle activity for rehabilitation with kinematic monitoring is disclosed. The system runs an efficient quaternion-based complementary filter that estimates the sensor orientation while correcting for estimate drift and constraining magnetometer estimates to only influence heading. The difference in the two sensor orientations is used to estimate the joint angle, which can be further improved with joint axis estimation. Thus, successful tracking of joint angle and muscle activity in a home environment can be accomplished with the sensors and a smartphone. Further, a system utilizing these sensors may include video-capable cameras configured for capturing a video of a pose of the user, and a game framework executable by a processor in communication with the sensors and the cameras. The system may include a game framework configured to utilize a pose trajectory and one or more joint angles determined using the sensors to provide biofeedback to a user.

Peptid analoge, die einen siebengliedrigen lactamring enthalten

Piperazin-4-phenyl-derivate als inhibitoren der wechselwirkung zwischen mdm2 und mdm2

Padded articles

Peptid derivate

Peptide compounds useful for treating MHC class II dependent T-cell medicated autoimmune or inflammatory diseases and pharmaceutical compositions containing same, and process for preparing same

A T-sejtek aktiválódását gátló peptidszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények

A találmány (I) általánős képletű, új peptidszármazékőkra ésgyógyászatilag alkalmazható sóikra vőnatkőzik, amelyek az aűtőimműnbetegségek és hasőnló rendellenességek kezelésében hasznősíthatófarmakőlógiai aktivitással rendelkeznek. A képletben P egy hidrőfóbmaradékőt jelent, R1 egy öt L-aminősavból álló szekvenciát ésűgyanakkőr R3 egyetlen L-aminősavat jelent, vagy R1 egy hárőm L-aminősavból álló szekvenciát és űgyanakkőr R3 egy hárőm L-aminősavbólálló szekvenciát jelent, R2 egy (II) vagy (III) általánős képletűcsőpőrtőt jelent, R4 hidrőxilcsőpőrtőt, aminőcsőpőrtőt vagy egy -NRcRdképletű csőpőrtőt jelent, amelyben Rd hidrőgénatőmőt vagyalkilcsőpőrtőt képvisel, és Rc jelentése alkil-, 2-karbamőil-ciklőpentil-, 2-piridil-metil-, 4-karbamőil-ciklőhexil-, 4-karbamőil-ciklőhexil-metil-, 3-karbamőil-fenil-, 4-karbamőil-fenil-, 4-(karbamőil-metil)-fenil-, 4-(karbőxi-metil)-fenil-, 4-(metőxi-karbőnil-metil)-fenil- vagy 2-mőrfőlinő-etil-csőpőrt, vagy Rc egy -A1-G1 képletű csőpőrtőt jelent, ahől A1 jelentése 3-7 szénatőmősalkiléncsőpőrt, vagy (1) -A2-B2- képletű csőpőrt, (2) -A3-B3-C3-képletű csőpőrt, és űgyanakkőr G1 -N=C[N(RP)2]2 csőpőrtőt jelent, vagyA1 -A4-B4- képletű csőpőrtőt jelent, és űgyanakkőr G1 2-mőrfőlinő-etil- vagy 4-[2-(2-hidrőxi-etőxi)-etil]-piperazin-1-il-csőpőrtőtjelent, vagy R4 1-piperazinil-, 4-metil-1-piperazinil-, 4-amidinő-1-piperazinil-, 4-[2-(2-hidrőxi-etőxi)-etil]-1-piperazinil- vagy 1-piperidil-csőpőrtőt vagy a 4-es helyzetben karbőxil-, karbamőil-, N-(2-aminő-etil)-karbamőil- vagy N-(4-aminő-bűtil)-karbamőil-csőpőrttalszűbsztitűált 1-piperidil-csőpőrtőt jelent, vagy R4 egy 1-6aminősavból álló szekvenciát vagy annak amidját jelenti. ŕ

Systems and methods for electromyogram-based control using neural networks

An EMG-based control system is disclosed. The system includes an EMG sensor that streams data to a device. A neural network executed by the device decodes muscle activity into a two-dimensional continuous control signal. A network-based calibration routine optimizes the neural network to decode natural movements of the user.

Peptide analogues containing a 7-membered lactam ring

The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P-R?1-R2-R3-R4¿, in which P, R?1, R2, R3, and R4¿ have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Piperazine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and p53

A compound of formula (1), wherein: R5 is hydrogen, C1-4alkyl, R6CH2- or R6C(O)-; R6 is aryl, heteroaryl, heterocyclyl, aminoC3-6alkyl, N-(C1-4alkyl)aminoC3-6alkyl, NN-(diC1-4alkyl)aminoC3-6alkyl, or R7; wherein the aryl, heteroaryl or heterocyclyl rings may be optionally substituted with up to three substituents independently selected from nitro, C1-4alkyl, C1-4alkoxy, halo, (C1-4alkyl)sulfanyl, C1-4alkoxycarbonyl, N-(C1-4alkyl)carbamoyl, NN-(diC1-4alkyl)carbamoyl, N-(C1-4alkyl)amino or NN-(diC1-4alkyl)amino; wherein R7 is either a group or formula (2) or formula (3); and wherein L1, L2, L3, L4, R1, R2, R3, R4, R8, R9, R10, R11, R12, R13, A1, n, p, q, r and s are as defined herein. The compounds of formula (1) inhibit the interactions between MDM2 and p53 and may be useful in the treatment of cancers.

Compound storage

The invention relates to adsorbing chemical samples onto inert carriers to form highly stable free flowing solid for long term storage in, for example, a proprietary compound collection.

Compound storage

The invention relates to adsorbing chemical samples onto inert carriers to form highly stable free flowing solid for long term storage in, for example, a proprietary compound collection.

Inhibitore der peptidbindung an mhc class ii proteine

Electrical control circuit for three-phase load device

Peptidderivate

Peptide derivatives.

Peptide derivatives.

Electrical control circuit for three-phase load device

Polypeptider, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater der indeholder dem samt anvendelse deraf til fremstilling af et laegemiddel

Polypeptider, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater der indeholder dem samt anvendelse deraf til fremstilling af et laegemiddel

Power bipolar transistor